References
- Emerman CL, Devlin C, Connors AF. Risk of toxicity in patients with elevated theophylline levels. Ann Emerg Med 1990: 19(6): 643–8
- Niewoehner DE. Theophylline therapy: a continuing dilemma. (Editorial) Chest 1990: 98(1): 5
- Murciano D, Auclair MH, Pariente R, et al. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989: 320(23): 1521–5
- Mahler DA. The role of theophylline in the treatment of dyspnea in COPD. Chest 1987: 92(1 Suppl): 2–6S
- Rogers RM, Owens GR, Pennock BE. The pendulum swings again: toward a rational use of theophylline. (Editorial) Chest 1985: 87(3): 280–2
- Georgopoulos D, Wong D, Anthonisen NR. Tolerance to β2-agonists in patients with chronic obstructive pulmonary disease. Chest 1990: 97(2): 280–4
- Hudson LD, Monti CM. Rationale and use of corticosteroids in chronic obstructive pulmonary disease. Med Clin North Am 1990: 74(3): 661–89
- Idell S, Kronenberg RS. Drug therapy for chronic obstructive pulmonary disease. Semin Respir Med 1986: 8(2): 129–39
- Cugell DW. Clinical pharmacology and toxicology of ipratropium bromide. Am J Med 1986: 81 (Suppl 5A): 18–27
- Tashkin DP, Ashutosh K, Bleecker ER, et al. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease: a 90-day multi-center study. Am J Med 1986: 81(5A): 81–90
- Annesi I, Kauffmann F. Is respiratory mucus hypersecretion really an innocent disorder? A 22-year mortality survey of 1,061 working men. Am Rev Respir Dis 1986: 134(4): 688–93
- Petty TL. The National Mucolytic Study: results of a randomized, double-blind, placebo- controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990: 97(1): 75–83